1
|
Chua N, Wong YH, El Sahili A, Liu CF, Lescar J. On the design of a constitutively active peptide asparaginyl ligase for facile protein conjugation. FEBS Open Bio 2023. [PMID: 36788723 DOI: 10.1002/2211-5463.13575] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 01/24/2023] [Accepted: 02/13/2023] [Indexed: 02/16/2023] Open
Abstract
Peptide asparaginyl ligases (PALs) are precision tools for peptide cyclization, cell-surface labelling, protein semi-synthesis and protein conjugation. PALs are expressed as inactive proenzymes requiring low pH activation. During activation, a large portion of the cap domain of the proenzyme that covers the substrate binding site is proteolytically removed, exposing the active site to solvent and releasing a population of heterogenous active enzymes. The availability of a readily active ligase not requiring acid-activation and subsequent purification of active forms would facilitate manufacturing and streamline applications. Here, we engineered the OaAEP1b-C247A hyperactive ligase via serial truncations along the linker connecting the cap and core domain of the proenzyme. Recombinant expression of the truncated constructs was carried out in E. coli. Following a solubilization/refolding protocol, one truncated construct termed "OaAEP1b-C247A-𝚫351" could be overexpressed in the insoluble fraction, purified, and displayed a level of ligase activity comparable to the acid-activated OaAEP1b-C247A enzyme. This constitutively active protein can be stored for up to two years at -80°C and readily used for peptide cyclization and protein conjugation. We were able to express and purify a stable constitutively active asparaginyl ligase that can be stored for months without significant activity loss. The removal of the low pH proenzyme activation step eliminates the heterogeneity introduced by this procedure. The yield of purified recombinant active ligase that can be routinely obtained per 100 millilitres of E. coli cell culture is about 0.9 mg. This recombinant active ligase can be used to carry out protein conjugation.
Collapse
Affiliation(s)
- Niying Chua
- School of Biological Sciences, Nanyang Technological University. 60 Nanyang Drive, Singapore, 637551.,NTU Institute of Structural Biology, Experimental Medicine Building, 59 Nanyang Drive, Singapore, 636921
| | - Yee Hwa Wong
- School of Biological Sciences, Nanyang Technological University. 60 Nanyang Drive, Singapore, 637551.,NTU Institute of Structural Biology, Experimental Medicine Building, 59 Nanyang Drive, Singapore, 636921
| | - Abbas El Sahili
- School of Biological Sciences, Nanyang Technological University. 60 Nanyang Drive, Singapore, 637551.,NTU Institute of Structural Biology, Experimental Medicine Building, 59 Nanyang Drive, Singapore, 636921
| | - Chuan Fa Liu
- School of Biological Sciences, Nanyang Technological University. 60 Nanyang Drive, Singapore, 637551
| | - Julien Lescar
- School of Biological Sciences, Nanyang Technological University. 60 Nanyang Drive, Singapore, 637551.,NTU Institute of Structural Biology, Experimental Medicine Building, 59 Nanyang Drive, Singapore, 636921
| |
Collapse
|
2
|
Abraham AG, Joseph K, Spratlin JL, Zebak S, Alba V, Iafolla M, Ghosh S, Abdelaziz Z, Lui A, Paulson K, Bedard E, Chua N, Tankel K, Koski S, Scarfe A, Severin D, Zhu X, King K, Easaw JC, Mulder KE. Does Loosening the Inclusion Criteria of the CROSS Trial Impact Outcomes in the Curative-Intent Trimodality Treatment of Oesophageal and Gastroesophageal Cancer Patients? Clin Oncol (R Coll Radiol) 2022; 34:e369-e376. [PMID: 35680509 DOI: 10.1016/j.clon.2022.05.011] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2022] [Revised: 04/16/2022] [Accepted: 05/13/2022] [Indexed: 11/28/2022]
Abstract
AIM To determine the efficacy of preoperative chemoradiotherapy as per the CROSS protocol for oesophageal/gastroesophageal junction cancer (OEGEJC), when expanded to patients outside of the inclusion/exclusion criteria defined in the original clinical trial. MATERIALS AND METHODS Data were collected retrospectively on 229 OEGEJC patients referred for curative-intent preoperative chemoradiotherapy. Outcomes including pathological complete response (pCR), overall survival (OS), cancer-specific survival and recurrence-free survival (RFS) of patients who met CROSS inclusion criteria (MIC) versus those who failed to meet criteria (FMIC) were determined. RESULTS In total, 42.8% of patients MIC, whereas 57.2% FMIC; 16.6% of patients did not complete definitive surgery. The MIC cohort had higher rates of pCR, when compared with the FMIC cohort (33.3% versus 20.6%, P = 0.039). The MIC cohort had a better RFS, cancer-specific survival and OS compared with the FMIC cohort (P = 0.006, P = 0.004 and P = 0.009, respectively). Age >75 years and pretreatment weight loss >10% were not associated with a poorer RFS (P = 0.541 and 0.458, respectively). Compared with stage I-III patients, stage IVa was associated with a poorer RFS (hazard ratio (HR) = 2.158; 95% confidence interval (CI) = 1.339-3.480, P = 0.001). Tumours >8 cm in length or >5 cm in width had a trend towards worse RFS (HR = 2.060; 95% CI = 0.993-4.274, P = 0.052). CONCLUSION Our study showed that the robust requirements of the CROSS trial may limit treatment for patients with potentially curable OEGEJC and can be adapted to include patients with a good performance status who are older than 75 years or have >10% pretreatment weight loss. However, the inclusion of patients with celiac nodal metastases or tumours >8 cm in length or >5 cm in width may be associated with poor outcomes.
Collapse
Affiliation(s)
- A G Abraham
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - K Joseph
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - J L Spratlin
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - S Zebak
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - V Alba
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; University of Alberta, Edmonton, Alberta, Canada
| | - M Iafolla
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; Department of Medical Oncology, Juravinski Cancer Center, McMaster University, Hamilton, Ontario, Canada
| | - S Ghosh
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - Z Abdelaziz
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; Department of Clinical Oncology, Cairo University, Cairo, Egypt
| | - A Lui
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - K Paulson
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - E Bedard
- Department of Thoracic Surgery, Royal Alexandra Hospital, University of Alberta, Edmonton, Alberta, Canada
| | - N Chua
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - K Tankel
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - S Koski
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - A Scarfe
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - D Severin
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - X Zhu
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - K King
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - J C Easaw
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada
| | - K E Mulder
- Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
| |
Collapse
|
3
|
Pan Y, Liu Z, Wang Y, Zhang L, Chua N, Dai L, Chen J, Ho CL. Evaluation of the Anti-Inflammatory and Anti-Oxidative Effects of Therapeutic Human Lactoferrin Fragments. Front Bioeng Biotechnol 2021; 9:779018. [PMID: 34917601 PMCID: PMC8671034 DOI: 10.3389/fbioe.2021.779018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2021] [Accepted: 11/01/2021] [Indexed: 01/11/2023] Open
Abstract
Chronic inflammation is considered a pressing health issue that needs resolving. Inflammatory disease such as inflammatory bowel disease requires a long-term medical regimen to prevent disease progression. Conventionally, lactoferrin is used to treat mild gastrointestinal tract and skin inflammation. Protease-digested lactoferrin fragments often exhibit improved therapeutic properties compared to full-length lactoferrin (flHLF). However, there are no studies on the use of protease-digested lactoferrin fragments to treat inflammation. Herein, we assess the anti-inflammatory properties of engineered recombinant lactoferrin fragments (rtHLF4, rteHLF1, and rpHLF2) on non-malignant colonic fibroblast cells and colorectal cancer cells. We found that rtHLF4 is 10 times more effective to prevent inflammation compared to flHLF. These results were investigated by looking into the reactive oxygen species (ROS) production, angiogenesis activity, and cellular proliferation of the treated cells. We have demonstrated in this study the anti-inflammatory properties of the flHLF and the various lactoferrin fragments. These results complement the anti-cancer properties of these proteins that were demonstrated in an earlier study.
Collapse
Affiliation(s)
- Yu Pan
- Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China
| | - Zhao Liu
- Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China
| | - Yijie Wang
- Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China
| | - Linshen Zhang
- Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China
| | - Niying Chua
- School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
| | - Lei Dai
- CAS Key Laboratory of Quantitative Engineering Biology, Chinese Academy of Sciences, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology (SIAT), Shenzhen, China
| | - Jun Chen
- Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China
| | - Chun Loong Ho
- Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China
| |
Collapse
|
4
|
Abstract
Protease-digested lactoferrin fragments often exhibit improved therapeutic properties. However, there are limited studies investigating the anticancer properties of these fragments. The fragment with improved anticancer activities is an attractive alternative to chemotherapeutic drugs-presenting severe side effects. Herein, we report the isolation and characterization of recombinant engineered-lactoferrin (rtHLF4), exhibiting up to 100-fold improved anticancer activity compared to the full-length lactoferrin (flHLF). Further, rtHLF4 exerts its anticancer effect in a shorter duration. Through transcriptomic analysis of various cancer biomarkers, rtHLF4 was found to upregulate various pro-apoptotic markers and downregulate signaling proteins involved in angiogenesis and metastasis. We further determined that rtHLF4 showed no hemolytic activity at high concentrations. We believe that this anticancer protein can be further developed as a cancer treatment.
Collapse
Affiliation(s)
- Yu Pan
- Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China
| | - Niying Chua
- School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive 637551, Jurong West, Singapore
| | - Kaisheng Lim
- Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China
| | - Chun Loong Ho
- Department of Biomedical Engineering, Southern University of Science and Technology (SUSTech), Shenzhen, China
| |
Collapse
|
5
|
Hotte S, Winquist E, Lemieux B, Laurie S, Bouganim N, Chua N, Brassard M, Ruether J, Lamond N, Ezzat S, Klimo P, Lim H, Massicotte MH, Wong R, Lam P, Yap B, Krzyzanowska M. Prescription and treatment patterns of lenvatinib (L) in patients with radioactive iodine-refractory differentiated thyroid cancer (rDTC): A retrospective analysis of the Canadian Patient Support Program (PSP). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz267.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Beattie WS, Wijeysundera DN, Chan MTV, Peyton PJ, Leslie K, Paech MJ, Sessler DI, Wallace S, Myles PS, Galagher W, Farrington C, Ditoro A, Baulch S, Sidiropoulos S, Bulach R, Bryant D, O’Loughlin E, Mitteregger V, Bolsin S, Osborne C, McRae R, Backstrom M, Cotter R, March S, Silbert B, Said S, Halliwell R, Cope J, Fahlbusch D, Crump D, Thompson G, Jefferies A, Reeves M, Buckley N, Tidy T, Schricker T, Lattermann R, Iannuzzi D, Carroll J, Jacka M, Bryden C, Badner N, Tsang MWY, Cheng BCP, Fong ACM, Chu LCY, Koo EGY, Mohd N, Ming LE, Campbell D, McAllister D, Walker S, Olliff S, Kennedy R, Eldawlatly A, Alzahrani T, Chua N, Sneyd R, McMillan H, Parkinson I, Brennan A, Balaji P, Nightingale J, Kunst G, Dickinson M, Subramaniam B, Banner-Godspeed V, Liu J, Kurz A, Hesler B, Fu AY, Egan C, Fiffick AN, Hutcherson MT, Turan A, Naylor A, Obal D, Cooke E. Implication of Major Adverse Postoperative Events and Myocardial Injury on Disability and Survival. Anesth Analg 2018. [DOI: 10.1213/ane.0000000000003310] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
7
|
Chua N, Khir R, Chong P, Lim C, Rizwal J, Abdul Rahman E, Aiza H, Mohd Arshad M, Ibrahim Z, Embong F, Lee C, Kasim S. Young Acute Coronary Syndrome Risk Factors and Outcome. Int J Cardiol 2017. [DOI: 10.1016/j.ijcard.2017.09.128] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Samban BNA, Muzzani A, Ruslan S, Razak N, Ibrahim Z, Khir R, Rizwal J, Chua N, Ibrahim K, Zainal Abidin Z, Lim C, Abdul Rahman E, Arshad K, Ghazi A, Kasim S. Quality of Life Among Revascularised Patients: CABG Versus PCI. Int J Cardiol 2017. [DOI: 10.1016/j.ijcard.2017.09.074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Ahmad A, Chua N, Khir R, Chong P, Lim C, Rizwal J, Abdul Rahman E, Aiza H, Mohd Arshad M, Ibrahim Z, Embong F, Lee C, Kasim S. Impact of Cholesterol Levels on Acute Coronary Syndrome Mortality in North of Kuala Lumpur. Int J Cardiol 2017. [DOI: 10.1016/j.ijcard.2017.09.119] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Zainal Abidin H, Isa M, Mohd Arshad M, Ibrahim Z, Ibrahim K, Ismail J, Chua N, Najme Khir R, Lim C, Abd Rahman E, Kasim S. Guideline Adherence to Prescription in Heart Failure Population in North Kuala Lumpur Region. Int J Cardiol 2017. [DOI: 10.1016/j.ijcard.2017.09.135] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Raja Shariff R, Chua N, Khir R, Ibrahim K, Mohd Arshad M, Lim C, Rizwal J, Abdul Rahman E, Aiza H, Ibrahim Z, Kasim S. Body Mass Index and Waist Circumference as Predictive Factors in the Development of Acute Coronary Syndrome in Young Adults. Int J Cardiol 2017. [DOI: 10.1016/j.ijcard.2017.09.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
12
|
Chua N, Mohd Arshad M, Khir R, Lim C, Rizwal J, Abdul Rahman E, Aiza H, Ibrahim Z, Kasim S. Procedural Safety and One Month Outcome of Patients Treated with Magnesium Bioresorbable Scaffold. Int J Cardiol 2017. [DOI: 10.1016/j.ijcard.2017.09.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Chua N, Khir R, Chong P, Lim C, Rizwal J, Abdul Rahman E, Aiza H, Mohd Arshad M, Ibrahim Z, Embong F, Lee C, Kasim S. Underoptimized Prior Statin Therapy in Acute Coronary Syndrome. Int J Cardiol 2017. [DOI: 10.1016/j.ijcard.2017.09.129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
14
|
Ahmad Tarmizi N, Chua N, Abdullah A, Kassim S. Risk Factors and Outcome of Acute Coronary Syndrome in the Elderly: A Malaysian Perspective. Int J Cardiol 2017. [DOI: 10.1016/j.ijcard.2017.09.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Peters A, Olateju T, Deschenes J, Shankarnarayan SH, Chua N, Shapiro AMJ, Senior P. Posttransplant Lymphoproliferative Disorder After Clinical Islet Transplantation: Report of the First Two Cases. Am J Transplant 2017; 17:2474-2480. [PMID: 28390107 DOI: 10.1111/ajt.14303] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Revised: 03/27/2017] [Accepted: 04/01/2017] [Indexed: 01/25/2023]
Abstract
We report the first two cases of posttransplant lymphoproliferative disorder (PTLD) in recipients of islet transplants worldwide. First, a 44-year-old recipient of three islet infusions developed PTLD 80 months after his initial transplantation, presenting with abdominal pain and diffuse terminal ileum thickening on imaging. He was treated with surgical excision, reduction of immunosuppression, and rituximab. Seven months later, he developed central nervous system PTLD, presenting with vertigo and diplopia; immunosuppression was discontinued, resulting in graft loss, and he was given high-dose methotrexate and underwent consolidative autologous stem cell transplantation. He remains in remission 37 months after the initial diagnosis. Second, a 58-year-old female recipient of two islet infusions developed PTLD 24 months after initial islet infusion, presenting with pancytopenia secondary to extensive bone marrow involvement. Immunosuppression was discontinued, resulting in graft loss, and she received rituximab and chemotherapy, achieving complete remission. Both patients were monomorphic B cell PTLD subtype by histology and negative for Epstein-Barr virus in tissue or blood. These cases document the first occurrences of this rare complication in islet transplantation, likely secondary to prolonged, intensive immunosuppression, and highlight the varying clinical manifestations of PTLD. Further studies are needed to determine incidence rate and risk factors in islet transplantation.
Collapse
Affiliation(s)
- A Peters
- Division of Clinical Hematology, Department of Medicine, University of Alberta, Edmonton, Canada
| | - T Olateju
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Canada
| | - J Deschenes
- Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada
| | - S H Shankarnarayan
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Canada
| | - N Chua
- Department of Oncology, University of Alberta, Edmonton, Canada
| | - A M J Shapiro
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Canada
| | - P Senior
- Clinical Islet Transplant Program, University of Alberta, Edmonton, Canada.,Division of Endocrinology, Department of Medicine, University of Alberta, Edmonton, Canada
| |
Collapse
|
16
|
Kostakoglu L, Martelli M, Belada D, Carella A, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Sehn L, Shi Y, Tatsumi Y, Fingerle-Rowson G, Mattiello F, Nielsen T, Sahin D, Vitolo U, Trněný M. END OF TREATMENT PET-CT PREDICTS PROGRESSION-FREE SURVIVAL IN DLBCL AFTER FIRST-LINE TREATMENT: RESULTS FROM THE PHASE III GOYA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_45] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- L. Kostakoglu
- Department of Radiology; Icahn School of Medicine at Mount Sinai; New York USA
| | - M. Martelli
- Department of Cellular Biotechnologies and Hematology; Sapienza University; Rome Italy
| | - D. Belada
- 4th Department of Internal Medicine-Hematology; University Hospital Hradec Kralove, and Charles University in Prague, Faculty of Medicine in Hradec Kralove; Hradec Kralove Czech Republic
| | - A.M. Carella
- U.O. Hematology I; IRCCS AO University, San Martino-IST; Genoa Italy
| | - N. Chua
- Cross Cancer Institute; University of Alberta; Edmonton Canada
| | - E. Gonzalez-Barca
- Institut Catalá d'Oncologia Hospitalet, IDIBELL; University of Barcelona; Barcelona Spain
| | - X. Hong
- Department of Medical Oncology; Fudan University Shanghai Cancer Center; Shanghai China
| | - A. Pinto
- Istituto Nazionale Tumori, Fondazione G. Pascale; IRCCS; Naples Italy
| | - L.H. Sehn
- Centre for Lymphoid Cancer; British Columbia Cancer Agency and the University of British Columbia; Vancouver Canada
| | - Y. Shi
- National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs; Beijing China
| | - Y. Tatsumi
- Department of Hematology and Rheumatology, Faculty of Medicine; Kinki University Hospital; Osaka Japan
| | - G. Fingerle-Rowson
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - F. Mattiello
- Pharma Development Biometrics Biostatistics; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - T. Nielsen
- Pharma Development Clinical Oncology; F. Hoffmann-La Roche Ltd; Basel Switzerland
| | - D. Sahin
- Department of Hematology and Rheumatology, Faculty of Medicine; Kinki University Hospital; Osaka Japan
| | - U. Vitolo
- Department of Hematology; Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - M. Trněný
- Department of Medicine-Department of Hematology; Charles University; Prague Czech Republic
| |
Collapse
|
17
|
Kam K, Castillo B, Chua N, Sanders H, Rapoport DM, Ayappa I, Osorio RS, Varga AW. 0268 ROLE OF INTERMITTENT HYPOXIA AND SLEEP FRADMENTATION FROM OSA DURING SLOW WAVE SLEEP ON SPATIAL MEMORY. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.267] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
18
|
Brand M, Stefanidis A, Morbach C, Fan YT, Elremisy DRA, Kuznetsov VA, Carrero C, Almodares Q, Abdulrahim H, Galli E, Galli E, Moreno J, Lerena Saenz P, Ikonomidis I, Galuszka OM, Bonapace S, Clerc OF, Kuznetsov VA, Tadic S, Kataoka A, Abdul Rahman E, Calin A, Antonini-Canterin F, Schwartzenberg SS, Christ M, Roeing J, Amirie S, Grett M, Beko M, Breker I, Wennemann R, Trappe HJ, Lagoudakou S, Vintzilaios K, Mokadem N, Vlachou J, Komatanou E, Korlou P, Kakkavas A, Komninos K, Kranidis A, Gelbrich G, Simon J, Cramer M, Knobeloch F, Tiffe T, Wagner M, Heuschmann PU, Stoerk S, Yang D, Wang X, Chan AK, Cheung SH, Lee AP, Salim FF, Bakhoum SW, Ashour ZA, Soldatova AM, Krinochkin DV, Enina TN, Altamirano C, Pipkin M, Constantin I, Fava A, Diaz Babio G, Masson Juarez G, San Miguel J, Vera Janavel G, Stutzbach P, Wallentin Guron C, Thurin A, Fu M, Kontogeorgos S, Thunstrom E, Johansson MC, Da Silva C, Venkateshvaran A, Nagy AI, Lund LH, Manouras A, Leclercq C, Fournet M, Bernard A, Mabo P, Samset E, Hernandez A, Donal E, Leclercq C, Fournet M, Bernard A, Mabo P, Samset E, Hernandez A, Donal E, Martinez Lugo CML, Zuniga Sedano JZD, Alexanderson EAR, Camilletti JC, Ahmed Abdelrahman M, Raslan H, Ruisanchez Villar C, Cuesta Cosgalla JM, Zarauza Navarro J, Veiga Fernandez G, Rifaie O, Omar AMS, Vlastos D, Frogoudaki A, Vrettou AR, Vlachos S, Varoudi M, Triantafyllidi H, Parissis J, Tsivgoulis G, Lekakis J, Steffens D, Friebel J, Rauch-Krohnert U, Landmesser U, Kasner M, Adamo E, Valbusa F, Ciccio' C, Rossi A, Lanzoni L, Chiampan A, Cecchetto A, Canali G, Barbieri E, Fuchs TA, Stehli J, Benz DC, Graeni C, Buechel RR, Kaufmann PA, Gaemperli O, Yaroslavskaya EI, Krinochkin DV, Kolunin GV, Gorbatenko EA, Dyachkov SM, Jung R, Ilic A, Stojsic-Milosavljevic A, Dejanovic J, Stefanovic M, Stojsic S, Sladojevic M, Watanabe Y, Kozuma K, Yamamoto M, Takagi K, Araki M, Tada N, Shirai S, Tamanaka F, Hayashida K, Ewe SH, Fadzil MA, Najme Khir R, Ismail JR, Lim CW, Chua N, Ibrahim ZO, Kasim SS, Ding ZP, Mateescu AD, Beladan CC, Rosca M, Enache R, Calin C, Cosei I, Botezatu S, Simion M, Ginghina C, Popescu BA, Di Nora C, Poli S, Vriz O, Zito C, Carerj S, Pavan D, Vaturi M, Kazum S, Monakier D, Sagie A, Kornowski R, Shapira Y. Poster Session 2The imaging examination and quality assessmentP520Benefit of early basic transthoracic echocardiography (TTE) in emergency patients performed by physicians with low to intermediate TTE experienceP521Appropriateness criteria in echocardiography. A contemporary necessity in clinical practiceP522Interobserver variability in 2d transthoracic echocardiography impact of scanning and reading on total variability results from the STAAB cohort study quality controlP5233D printing for personalised planning of catheter-based left atrial appendage occlusionP524Central obesity: an independent role or synergistic effect to metabolic syndrome on right atrial structure?P525Dynamics of left ventricular volumes and mortality in patients with early and late effect of cardiac resynchronization therapyP526Variability of thoracic aortic diameters according to gender, age and body surface area. Time to forget absolute cut-off values?P527The association of left ventricular outflow tract velocity time integral to all-cause mortality in elderly patients with heart failureP528Left ventricular myocardial performance and atrioventricular coupling in patients with primary arterial hypertensionP529Interest of a combinatory approach based on traditional left ventricular dyssynchrony parameters and cardiac work estimated by pressure-strain loop curves for the prediction of cardiac resynchronizatP530The evaluation of cardiac performance by pressure-strain loops: a useful tool for the identification of cardiac resynchronization therapy respondersP531Left ventricle cardiac function by 2D-speckle tracking echocardiography in diabetes mellitus population: sub-clinical systolic disfunction studyP532Biphasic tissue doppler mitral annular isovolumic contraction velocities are associated with left ventricular function, isovolumic relaxation, and pulmonary wedge pressure in heart failure patientsP533Abnormal left atrial volumes and strains are associated with increased arterial stiffnes in patients with cryptogenic stroke: a novel pathophysiological pathP534Detection of coronary microvascular disease using two-dimensional speckle-tracking echocardiographyP535Predictive value of a bi-dimensional transthoracic echocardiographic sign of " binary image" to identify the anomalous origin of the left circumflex coronary artery from the right coronary sinusP536Systematic review and meta-analysis of screening for coronary artery disease in asymptomatic diabetic patientsP537Noninvasive screening test for diagnosis of nonobstructive coronary artery disease using echocardiographic criteriaP538Early echocardiography after primary angioplasty, important role in predicting left ventricular remodelingP539Prognostic impact of low-flow severe aortic stenosis in Japanese patients undergoing transcatheter aortic valve implantation: the ocean-tavi registryP540Left ventricular outflow tract geometry and its impact on aortic valve area calculations in aortic stenosis using 3D transoesophageal echocardiography and 2D transthoracic echocardiographyP541Impaired left atrial myocardial deformation predicts postoperative atrial fibrillation after aortic valve replacement in patients with aortic stenosisP542Ejection fraction-velocity ratio in predicting symptoms in severe aortic stenosisP543Incremental value of transesophageal echocardiography in conjunction with transthoracic echocardiography in the assessment of aortic stenosis severity. Eur Heart J Cardiovasc Imaging 2016. [DOI: 10.1093/ehjci/jew248] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
19
|
Harris JR, Lau H, Surgeoner BV, Chua N, Dobrovolsky W, Dort JC, Kalaydjian E, Nesbitt M, Scrimger RA, Seikaly H, Skarsgard D, Webster MA. Health care delivery for head-and-neck cancer patients in Alberta: a practice guideline. ACTA ACUST UNITED AC 2014; 21:e704-14. [PMID: 25302041 DOI: 10.3747/co.21.1980] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
BACKGROUND The treatment of head-and-neck cancer is complex and requires the involvement of various health care professionals with a wide range of expertise. We describe the process of developing a practice guideline with recommendations about the organization and delivery of health care services for head-and-neck cancer patients in Alberta. METHODS Outcomes of interest included composition of the health care team, qualification requirements for team members, cancer centre and team member volumes, infrastructure needs, and wait times. A search for existing practice guidelines and a systematic review of the literature addressing the organization and delivery of health care services for head-and-neck cancer patients were conducted. The search included the Standards and Guidelines Evidence (sage) directory of cancer guidelines and PubMed. RESULTS One practice guideline was identified for adaptation. Three additional practice guidelines provided supplementary evidence to inform guideline recommendations. Members of the Alberta Provincial Head and Neck Tumour Team (consisting of various health professionals from across the province) provided expert feedback on the adapted recommendations through an online and in-person review process. Selected experts in head-and-neck cancer from outside the province participated in an external online review. SUMMARY The recommendations outlined in this practice guideline are based on existing guidelines that have been modified to fit the Alberta context. Although specific to Alberta, the recommendations lend credence to similar published guidelines and could be considered for use by groups lacking the resources of appointed guideline panels. The recommendations are meant to be a guide rather than a fixed protocol. The implementation of this practice guideline will depend on many factors, including but not limited to availability of trained personnel, adequate funding of infrastructure, and collaboration with other associations of health care professionals in the province.
Collapse
Affiliation(s)
- J R Harris
- Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, AB
| | - H Lau
- Department of Oncology, Division of Radiation Oncology, University of Calgary, Calgary, AB
| | - B V Surgeoner
- Guideline Utilization Resource Unit, CancerControl Alberta, Alberta Health Services, Calgary, AB
| | - N Chua
- Department of Oncology, University of Alberta, Edmonton, AB
| | - W Dobrovolsky
- Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB
| | - J C Dort
- Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Calgary, Calgary, AB
| | - E Kalaydjian
- Department of Surgery, Section of Dentistry and Oral Health, Alberta Health Services, Calgary, AB
| | - M Nesbitt
- Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, AB
| | - R A Scrimger
- Department of Oncology, Division of Radiation Oncology, University of Alberta, Edmonton, AB
| | - H Seikaly
- Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, University of Alberta, Edmonton, AB
| | - D Skarsgard
- Department of Oncology, Division of Radiation Oncology, University of Calgary, Calgary, AB
| | - M A Webster
- Department of Oncology, University of Calgary, Calgary, AB
| | | |
Collapse
|
20
|
|
21
|
Chu M, Hecht J, Slamon D, Fontaine A, King K, Koski S, Mulder K, Hiller JP, Scarfe A, Spratlin J, Bang Y, Hoff P, Sobrero A, Qin S, Afenjar K, Houe V, Huang Y, Khan-Wasti S, Chua N, Sawyer M. Proton Pump Inhibitor (Ppis) Therapy May Impair Capecitabine (Cape) Efficacy in Metastatic Gastroesophageal Cancer (Gec), Results from the Trio-013/Logic Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu334.6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
22
|
Dueck GS, Chua N, Prasad A, Stewart D, White D, vanderJagt R, Johnston JB, Belch A, Reiman T. Activity of lenalidomide in a phase II trial for T-cell lymphoma: Report on the first 24 cases. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.8524] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8524 Background: Novel therapies are needed to improve outcomes in T-cell lymphomas. We report the interim results of a prospective multicenter trial evaluating lenalidomide in T-cell lymphomas. Methods: Patients with relapsed and refractory T-cell lymphomas other than mycosis fungoides were prescribed oral lenalidomide (25mg daily) on days 1 to 21 of each 28 day cycle, with standardized dose reductions for toxicity. Treatment continued until disease progression, death or unacceptable toxicity. The primary endpoint was overall response rate, and secondary endpoints were complete and partial response rates, progression-free and overall survival (PFS, OS), and safety. The two-stage design allows for up to 40 patients. Results: At the time of this interim analysis, 24 patients were enrolled in this study and 23 were evaluable for response. The median age was 65 years. ECOG PS was 0–1 (n=15), 2 (n=7), 3 (n=2). The histology was peripheral T-cell unspecified (PTCL-u, n=10), angioimmunoblastic (n=7), anaplastic large cell (n=5), enteropathic T-cell (n=1) and hepatosplenic gamma/delta (n=1). Median number of prior therapies was 1 (range, 0–4), and three had prior autologous stem cell transplant. Four patients were previously untreated and not candidates for combination chemotherapy. Median time from completion of prior therapy to the start of lenalidomide was 8 months (range, 1–48 months). The overall response rate was 7/23 (30%); all were partial responses. Two patients had stable disease (SD) for ≥3 cycles. Responses were seen in anaplastic, angioimmunoblastic, and PTCL-u histologies. Median PFS was 96 days (range, 8–696 days). Median OS was 241 days (range, 8–696+ days). Among the 9 patients with SD or better, median PFS was 168 days and median OS has not yet been reached with 241–696 days of follow-up. The most common grade 4 adverse event was thrombocytopenia (33.3%). The most common grade 3 adverse events were neutropenia (20.8%), febrile neutropenia (16.7%), and pain NOS (16.7%). Conclusions: In relapsed and refractory T-cell lymphomas, oral lenalidomide monotherapy has clinical activity and toxicity is consistent with the known profile of lenalidomide. Further study of lenalidomide in these diseases is warranted. [Table: see text]
Collapse
Affiliation(s)
- G. S. Dueck
- University of Alberta, Edmonton, AB, Canada; University of Calgary, Calgary, AB, Canada; Dalhousie University, Halifax, NS, Canada; University of Ottawa, Ottawa, ON, Canada; University of Manitoba, Winnipeg, MB, Canada; Saint John Regional Hospital, Saint John, NB, Canada
| | - N. Chua
- University of Alberta, Edmonton, AB, Canada; University of Calgary, Calgary, AB, Canada; Dalhousie University, Halifax, NS, Canada; University of Ottawa, Ottawa, ON, Canada; University of Manitoba, Winnipeg, MB, Canada; Saint John Regional Hospital, Saint John, NB, Canada
| | - A. Prasad
- University of Alberta, Edmonton, AB, Canada; University of Calgary, Calgary, AB, Canada; Dalhousie University, Halifax, NS, Canada; University of Ottawa, Ottawa, ON, Canada; University of Manitoba, Winnipeg, MB, Canada; Saint John Regional Hospital, Saint John, NB, Canada
| | - D. Stewart
- University of Alberta, Edmonton, AB, Canada; University of Calgary, Calgary, AB, Canada; Dalhousie University, Halifax, NS, Canada; University of Ottawa, Ottawa, ON, Canada; University of Manitoba, Winnipeg, MB, Canada; Saint John Regional Hospital, Saint John, NB, Canada
| | - D. White
- University of Alberta, Edmonton, AB, Canada; University of Calgary, Calgary, AB, Canada; Dalhousie University, Halifax, NS, Canada; University of Ottawa, Ottawa, ON, Canada; University of Manitoba, Winnipeg, MB, Canada; Saint John Regional Hospital, Saint John, NB, Canada
| | - R. vanderJagt
- University of Alberta, Edmonton, AB, Canada; University of Calgary, Calgary, AB, Canada; Dalhousie University, Halifax, NS, Canada; University of Ottawa, Ottawa, ON, Canada; University of Manitoba, Winnipeg, MB, Canada; Saint John Regional Hospital, Saint John, NB, Canada
| | - J. B. Johnston
- University of Alberta, Edmonton, AB, Canada; University of Calgary, Calgary, AB, Canada; Dalhousie University, Halifax, NS, Canada; University of Ottawa, Ottawa, ON, Canada; University of Manitoba, Winnipeg, MB, Canada; Saint John Regional Hospital, Saint John, NB, Canada
| | - A. Belch
- University of Alberta, Edmonton, AB, Canada; University of Calgary, Calgary, AB, Canada; Dalhousie University, Halifax, NS, Canada; University of Ottawa, Ottawa, ON, Canada; University of Manitoba, Winnipeg, MB, Canada; Saint John Regional Hospital, Saint John, NB, Canada
| | - T. Reiman
- University of Alberta, Edmonton, AB, Canada; University of Calgary, Calgary, AB, Canada; Dalhousie University, Halifax, NS, Canada; University of Ottawa, Ottawa, ON, Canada; University of Manitoba, Winnipeg, MB, Canada; Saint John Regional Hospital, Saint John, NB, Canada
| |
Collapse
|
23
|
Mathur J, Spielhofer P, Kost B, Chua N. The actin cytoskeleton is required to elaborate and maintain spatial patterning during trichome cell morphogenesis in Arabidopsis thaliana. Development 1999; 126:5559-68. [PMID: 10572033 DOI: 10.1242/dev.126.24.5559] [Citation(s) in RCA: 137] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Arabidopsis thaliana trichomes provide an attractive model system to dissect molecular processes involved in the generation of shape and form in single cell morphogenesis in plants. We have used transgenic Arabidopsis plants carrying a GFP-talin chimeric gene to analyze the role of the actin cytoskeleton in trichome cell morphogenesis. We found that during trichome cell development the actin microfilaments assumed an increasing degree of complexity from fine filaments to thick, longitudinally stretched cables. Disruption of the F-actin cytoskeleton by actin antagonists produced distorted but branched trichomes which phenocopied trichomes of mutants belonging to the ‘distorted’ class. Subsequent analysis of the actin cytoskeleton in trichomes of the distorted mutants, alien, crooked, distorted1, gnarled, klunker and wurm uncovered actin organization defects in each case. Treatments of wild-type seedlings with microtubule-interacting drugs elicited a radically different trichome phenotype characterized by isotropic growth and a severe inhibition of branch formation; these trichomes did not show defects in actin cytoskeleton organization. A normal actin cytoskeleton was also observed in trichomes of the zwichel mutant which have reduced branching. ZWICHEL, which was previously shown to encode a kinesin-like protein is thought to be involved in microtubule-linked processes. Based on our results we propose that microtubules establish the spatial patterning of trichome branches whilst actin microfilaments elaborate and maintain the overall trichome pattern during development.
Collapse
Affiliation(s)
- J Mathur
- Laboratory of Plant Cell Biology, Institute of Molecular Agrobiology, National University of Singapore, Singapore, 117 604
| | | | | | | |
Collapse
|
24
|
Smirnyagina E, Hsu YH, Chua N, Ahlquist P. Second-site mutations in the brome mosaic virus RNA3 intercistronic region partially suppress a defect in coat protein mRNA transcription. Virology 1994; 198:427-36. [PMID: 8291227 DOI: 10.1006/viro.1994.1054] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
An intercistronic oligo(A) tract is present in the genomic RNA3 of all bromoviruses sequenced to date and, for brome mosaic virus (BMV), is known to function as an activating sequence in transcription of the subgenomic coat protein mRNA, RNA4. Mutations able to partially compensate for removal of the oligo(A) from BMV RNA3 were identified by obtaining spontaneous second-site revertants. The starting BMV RNA3 mutant carried a deletion of 17 of 18 residues of the intercistronic oligo(A), resulting in a nearly complete loss of subgenomic coat protein mRNA synthesis and reduced RNA3 accumulation. The responsible suppressor mutations acted in cis and were located in the 244-base RNA3 intercistronic region containing the original deletion. Three mutations associated with the revertant phenotype were characterized: (i) A single U-->A substitution in the core subgenomic mRNA promoter restored 35% of wild-type promoter activity. (ii) A duplication of 8 bases (UAUUAUUA) immediately 5' to the oligo(A) deletion site resulted in higher levels of both RNA3 and RNA4 accumulation. (iii) A point substitution in a conserved cellular motif corresponding to box B of RNA polymerase III promoters reduced RNA3 accumulation. Together with certain intervirally conserved promoter sequences, the spontaneous adaptation of a bromovirus subgenomic promoter to function without its unusual oligo(A) activator suggests that bromovirus subgenomic mRNA transcription may share underlying mechanistic similarities with the many other members of the alphavirus-like superfamily, whose subgenomic promoters all lack an oligo(A) tract.
Collapse
Affiliation(s)
- E Smirnyagina
- Institute for Molecular Virology, University of Wisconsin-Madison 53706
| | | | | | | |
Collapse
|